Zydus Cadila receives nod from the USFDA for Phytonadione, Colchicine Tablets

21 Feb 2019 Evaluate

Zydus Cadila has received the final approval from the USFDA to market Phytonadione Tablets USP (US RLD - Mephyton), 5 mg. Phytonadione is Vitamin K1 and is used to treat & prevent low levels of blood clotting factors that the body naturally produces. These substances help in thickening of the blood and stop the bleeding normally.

The group also received the final approval for Colchicine Tablets USP (US RLD - Colcrys), 0.6 mg. Colchicine is used to prevent or treat attacks of gout (also called gouty arthritis). This condition is caused by high uric acid levels in the blood. An attack of gout occurs when uric acid causes inflammation (pain, redness and swelling) in a joint. This medication is also used to prevent attacks of pain in the abdomen, chest or joints caused by a genetic auto-inflammatory disease called as familial Mediterranean fever.

Both the products will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Zydus Lifesciences Share Price

931.45 -3.75 (-0.40%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×